Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>AbbVie Inc.</li><li>showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations.</li><li>The company's growth platform, independent of their iconic Humira, reported full-year sales growth exceeding 8%.</li></ul>

AbbVie Inc.showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations.The company's growth platform, independent of their iconic Humira, reported full-year sales growth exceeding 8%.

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

<ul><li>AbbVie Inc. managed to exceed Wall Street's revenue and earnings expectations, reinforcing a positive trajectory for long-term growth.</li><li>The recently reported results exemplify this strength, with adjusted earnings per share reaching $2.95, surpassing the guidance midpoint by $0.14.</li><li>The ex-HUMIRA growth platform stands out as a powerhouse, achieving remarkable revenue growth of over 12% in the quarter.</li></ul>

AbbVie Inc. managed to exceed Wall Street's revenue and earnings expectations, reinforcing a positive trajectory for long-term growth.The recently reported results exemplify this strength, with adjusted earnings per share reaching $2.95, surpassing the guidance midpoint by $0.14.The ex-HUMIRA growth platform stands out as a powerhouse, achieving remarkable revenue growth of over 12% in the quarter.

AbbVie Inc.: Is The Strengthening Neuroscience Pipeline The Key To Future Success? - Major Drivers

<ul><li>AbbVie managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.</li><li>Skyrizi and Rinvoq are exhibiting exceptional growth in immunology, with sales for both treatments increasing over the previous year.</li><li>Skyrizi and Rinvoq are now approved across ten significant indications and are projecting combined revenue growth this year.</li></ul>

AbbVie managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.Skyrizi and Rinvoq are exhibiting exceptional growth in immunology, with sales for both treatments increasing over the previous year.Skyrizi and Rinvoq are now approved across ten significant indications and are projecting combined revenue growth this year.

AbbVie Inc.: Interesting Advancements In Several Preclinical & Early-stage Clinical Assets – Key Drivers

<ul><li>AbbVie delivered a decent result in the first quarter of the year with revenues above Wall Street expectations and earnings in line with the analyst consensus.</li><li>Skyrizi and Rinvoq continued to perform well in the first quarter and are still on track to produce more than $11 billion in combined sales this year.</li><li>Growth rates for both products in the first quarter are in line with the company's estimation for the entire year.</li></ul>

AbbVie delivered a decent result in the first quarter of the year with revenues above Wall Street expectations and earnings in line with the analyst consensus.Skyrizi and Rinvoq continued to perform well in the first quarter and are still on track to produce more than $11 billion in combined sales this year.Growth rates for both products in the first quarter are in line with the company's estimation for the entire year.

AbbVie Inc.: Is The CytomX Collaboration Failure A Big Setback? – Key Drivers

Quantitative Equity Analyst, DMA

Charlotte van Tiddens, CFA

Quantitative Equity Analyst

Technology-First Company

DMA is a technology-first company that provides an end-to-end SaaS solution to institutional investors. DMA enables regulated entities like asset managers, wealth managers, investment managers and financial advisors to connect their front and back office, break silos and reduce headcount.

Quantitative Analysis

<ul>
<li>Short duration US factor strategies outperformed in September as markets came under pressure (value and dividend yield).</li>
<li>Despite keeping rates unchanged on the 20th of September at 5.5% (upper bound), Fed Chair Powell indicated that rates would be kept higher for longer than initially anticipated.</li>
<li>In this note we explore the <em><strong>relative performance</strong></em> of US factor strategies through different interest rate cycles, to inform timing around factor/style rotation.</li>
</ul>


Short duration US factor strategies outperformed in September as markets came under pressure (value and dividend yield).
Despite keeping rates unchanged on the 20th of September at 5.5% (upper bound), Fed Chair Powell indicated that rates would be kept higher for longer than initially anticipated.
In this note we explore the relative performance of US factor strategies through different interest rate cycles, to inform timing around factor/style rotation.


US Factor Strategies: Value and Dividend Yield Outperform in September, Higher for Longer Narrative

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Abbvie Inc (ABBV US)

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

AbbVie Inc. showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations. The company's...

Baptista Research

AbbVie Inc.: Is The Strengthening Neuroscience Pipeline The Key To Future Success? - Major Drivers

AbbVie Inc. managed to exceed Wall Street's revenue and earnings expectations, reinforcing a positive trajectory for long-term growth. The...

Baptista Research

AbbVie Inc.: Interesting Advancements In Several Preclinical & Early-stage Clinical Assets – Key Drivers

AbbVie managed to surpass the revenue expectations as well as the earnings expectations of Wall Street. Skyrizi and Rinvoq are exhibiting...

Baptista Research

AbbVie Inc.: Is The CytomX Collaboration Failure A Big Setback? – Key Drivers

AbbVie delivered a decent result in the first quarter of the year with revenues above Wall Street expectations and earnings in line with the...

Baptista Research

US Factor Strategies: Value and Dividend Yield Outperform in September, Higher for Longer Narrative

US rates and factor strategies: higher for longer likely to drive outperformance of short duration factor strategies, long US value short US growth.

DMA